A population-based study of the comparative effectiveness of second-generation antipsychotics vs older antimanic agents in bipolar disorder

2016 ◽  
Vol 18 (6) ◽  
pp. 481-489 ◽  
Author(s):  
Mark S Bauer ◽  
Christopher J Miller ◽  
Mingfei Li ◽  
Laura A Bajor ◽  
Austin Lee
Keyword(s):  
Bipolar Disorder ◽  
Comparative Effectiveness ◽  
Second Generation ◽  
Population Based ◽  
Population Based Study ◽  
Second Generation Antipsychotics

The use of second generation antipsychotics in children and adolescents with bipolar disorder and schizophrenia: A summary of the AHRQ comparative effectiveness review

2013 ◽  
Vol 2 (11) ◽  
pp. 350-352
Author(s):  
Jeani Pulsipher ◽  
Gary M. Levin
Keyword(s):  
Bipolar Disorder ◽  
Adverse Effects ◽  
Children And Adolescents ◽  
Mood Disorders ◽  
Comparative Effectiveness ◽  
Second Generation ◽  
Pediatric Patients ◽  
Healthcare Research ◽  
Second Generation Antipsychotics

Second generation antipsychotics (SGAs) can be effective in treating mood disorders in pediatric patients; however, these medications also present with a risk of serious adverse effects. A recent review by the Agency for Healthcare Research and Quality (AHRQ) evaluated the use of SGAs in pediatric patients. This article summarizes the findings of the review, with a focus on bipolar disorder and schizophrenia.

Metabolic syndrome in subjects with bipolar disorder and major depressive disorder in a current depressive episode: Population-based study

2017 ◽  
Vol 92 ◽  
pp. 119-123 ◽  
Author(s):  
Fernanda Pedrotti Moreira ◽  
Karen Jansen ◽  
Taiane de Azevedo Cardoso ◽  
Thaíse Campos Mondin ◽  
Pedro Vieira da Silva Magalhães ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Depressive Episode ◽  
Population Based ◽  
Major Depressive ◽  
Population Based Study ◽  
A Current

scholarly journals Second-generation antipsychotics and metabolic side-effects: Canadian population-based study

BJPsych Open ◽  
2018 ◽  
Vol 4 (4) ◽  
pp. 256-261 ◽  
Author(s):  
Lauren Hirsch ◽  
Scott B. Patten ◽  
Lauren Bresee ◽  
Nathalie Jette ◽  
Tamara Pringsheim
Keyword(s):  
Odds Ratio ◽  
Second Generation ◽  
Population Level ◽  
Population Based ◽  
Metabolic Dysfunction ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Canadian Population ◽  
Second Generation Antipsychotics ◽  
Canadian Health

BackgroundUse of second-generation antipsychotics (SGA) has increased in recent years; however, their use and effect on metabolic outcomes has been poorly characterised in population-level studies.AimsThis study aimed to determine the associations between SGA use and metabolic indicators in a general population.MethodWe used data from the Canadian Health Measures Survey, a cross-sectional survey of Canadian households. Participants were Canadians aged 3–79 years, living in one of the ten provinces. Several metabolic indicators were examined, including weight, body mass index, waist circumference, hypertension, diabetes and two definitions of metabolic syndrome.ResultsThe proportion of Canadians taking an SGA tripled over the study period. SGA use was significantly associated with hypertension (odds ratio 1.94, 95% CI 1.07–3.55) and abdominal obesity in adults, as defined by the National Cholesterol Education Program–Adult Treatment Panel III (odds ratio 2.62, 95% CI 1.45–4.71).ConclusionsEvidence of metabolic dysfunction with SGAs is seen in the Canadian population, along with a rapid increase in prevalence of use since 2007.Declaration of interestNone.

Sign in / Sign up

Export Citation Format

Share Document